TNF and chronic obstructive pulmonary disease: COPD patient subgroups expressing the highest baseline levels of CRP (top quartile, > 6.9 μg/ml) or TNF-alpha (top quartile, > 6.8 pg/ml) also did not demonstrate a significant impact of infliximab on changes in clinical and biomarker measurements (Table 4).